Navigating regulatory and legal risks in life science innovation

Innovation in life science operates inside demanding legal and regulatory frameworks.

Emerging technologies including AI have highlighted gaps in regulation, but for most businesses the bigger challenge is managing a wider set of obligations that can shift quickly as a business moves from R&D into trials, manufacturing, and commercial scale.

For brokers, this is a clear opportunity to help clients understand where regulatory and legal risk arises, spot common weak points early, and structure risk management and insurance so innovation can progress with confidence.

The regulatory landscape; high standards, evolving expectations

Life science businesses may face requirements around MHRA licensing and authorisations, safety reporting, quality processes, clinical governance, and sector-specific compliance regimes. Even businesses that don’t manufacture physical products may handle sensitive data, support clinical work via partners, or provide regulated services.

The broker’s job isn’t to interpret regulation, but to ask the right questions and identify where a client’s controls and documentation may not match the risk. In life science, weak governance can quickly become a commercial problem, delaying approvals, slowing partnerships, or shaking investor confidence.

Where legal risk often starts; accuracy, accountability, and contracts

The core issue for life science is around accountability and control. In regulated environments, errors can trigger serious consequences, from delays to claims and reputational harm.

Liability also needs to be clearly understood. The law generally requires a “legal personality” to bear legal responsibility, but you can’t sue a computer or a piece of software. In practice, responsibility sits with human and corporate actors: creators, suppliers and users.

That makes contracting critical. When a life science business procures a platform, tool, or outsourced service, the terms and conditions help determine how risk and liability are allocated if something goes wrong.

A useful broker prompt is: If this output is wrong, delayed, or compromised, who is accountable, what does the contract say and what is the escalation route?

Ethical governance, bias, and employment exposure

AI in particular has raised the profile of bias and discrimination risks in automated decision-making: although it can reduce individual human bias, it may reproduce biases in training data or narrow datasets, leading to unintended discriminatory outcomes.

For brokers, the takeaway is that legal exposure can appear in unexpected places, like HR processes, customer interactions, and automated decisioning, as well as clinical or product activity.

Intellectual property (IP) protection; safeguarding value in an evolving landscape

IP is central to life science value, and IP owners can enforce rights through injunctions and/or damages.

Brokers don’t need to advise on IP law, but they should recognise that IP disputes can be highly disruptive and expensive, especially for SMEs whose valuation is concentrated in a small number of assets.

Data protection and GDPR: transparency is the test

In principle, businesses can use AI if they meet the core principles of data protection laws, including the Data Protection Act 2018 and GDPR, and have a lawful basis for processing.

In practice, the common tripwire is fair and transparent processing, particularly where profiling or automated decision-making is involved. Businesses should be able to explain, in plain English, what data is used, why, who it’s shared with, and where AI is applied.

Good indicators brokers can look for include clear privacy notices, defined data ownership, access controls, and evidence of human oversight where decisions have significant effects.

How brokers can support clients: practical, repeatable steps

Regulatory and legal missteps can cascade quickly into legal liability and contractual disputes, financial penalties and remediation costs, and reputational harm with partners, investors, regulators, and customers.

In life science, that reputational tail can be long, particularly during fundraising, trials, or commercial launch.

Brokers add most value by encouraging disciplines that stand up under scrutiny:

• Proactive compliance and documentation; clear records of decisions, validations and responsibilities
• Governance frameworks; who approves new tools/processes, who monitors, and how issues are escalated
• Vendor and contract management; clear apportionment of responsibility and data handling obligations
• Training and awareness; helping teams understand regulatory and data risks, not just operational benefits
• Escalation protocols; agreed response routes for incidents, near misses, and compliance concerns

Where insurance fits: protecting the innovation pipeline

Insurance is only one part of the solution, but it can help protect balance sheets and keep innovation moving when incidents occur.

Depending on the client’s activities and stage, brokers may consider how the programme responds to exposures such as product liability, clinical trial-related risks, cyber and data incidents, and professional indemnity.

The broker’s role is to ensure cover aligns with how the business operates today and how it is likely to change over the next 12-18 months.

Final thought

AI has amplified the conversation, but the underlying challenge is broader: life science innovation must be matched with compliance, governance, and accountability.

Brokers who can help clients build that foundation, and structure protection that evolves with them, will be best placed to support sustainable growth in a high-opportunity, high-scrutiny sector.

Built for scrutiny and compliance

In a sector defined by scrutiny, insurance should support strong governance rather than sit apart from it. A specialist life science offering is built to align with regulatory complexity, helping brokers protect clients against legal, contractual, and data-related exposures as they innovate.